Physician profile
Natalie Michelle Wong
NPI 1619751930
$6,997.41
in general payments reported to CMS, 2019-2025
20 companies · $5,959 in 2025
The $5,959 reported for 2025 was more than what 97% of Psychiatric/Mental Health (Clinical Nurse Specialist) providers received nationally (typical 2025 total: $244).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,038 · 2025: $5,959.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,997.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,997.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $876.21 | 2024-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Vanda Pharmaceuticals INC. | $872.61 | 2024-2025 | Fanapt, Hetlioz |
| Abbvie INC. | $820.47 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $627.39 | 2024-2025 | Cobenfy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $501.01 | 2025 | Caplyta |
| Axsome Therapeutics, INC. | $458.65 | 2024-2025 | Auvelity |
| Neurocrine Biosciences, INC. | $455.38 | 2024-2025 | Ingrezza |
| Biogen, INC. | $427.80 | 2024-2025 | Zurzuvae |
| Janssen Pharmaceuticals, INC | $422.84 | 2025 | Invega Sustenna, Spravato, Invega Trinza |
| Teva Pharmaceuticals USA, INC. | $353.11 | 2024-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Alkermes, INC. | $324.30 | 2024-2025 | Aristada, Lybalvi, Aristada Initio |
| Luye Pharma (USA) Ltd. | $288.20 | 2025 | Erzofri Extended-Release |
| Corium, LLC | $141.75 | 2024-2025 | Azstarys |
| Supernus Pharmaceuticals, INC. | $124.97 | 2025 | Qelbree |
| Noven Therapeutics, LLC | $87.93 | 2024-2025 | Xelstrym |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $77.50 | 2024-2025 | Trintellix |
| Lundbeck LLC | $60.01 | 2024-2025 | Rexulti |
| Tris Pharma INC | $37.07 | 2024-2025 | Dyanavel Xr |
| Braeburn INC. | $22.03 | 2025 | Brixadi |
| Bausch Health US, LLC | $18.18 | 2025 | Aplenzin |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Natalie Wong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.